Establishment and Characterization of Meningioma Patient-derived Organoids

Meningioma Clinical Trial

Official title:

Establishment and Characterization of Meningioma Patient-derived Organoids

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04478877
• Other study ID #: GWMO01
• Status: Completed
• Start date: May 23, 2020
• Est. completion date: August 31, 2023

Study information

• Verified date: September 2023
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Description:

Aims and Hypothesis to be tested:

The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue.

Study period: 1 year for patient recruitment and organoid generation from patient tumor

Study population: 30

Study samples:

Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids

Primary outcome measures:

Whole exome sequencing data of patient tumor tissue and patients-derived organoids

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 31, 2023
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients (aged >18 years) with meningioma

2. Admission into Prince Wales hospitals neurosurgical services

3. Patients with surgical needs of meningioma removal

Exclusion Criteria:

1. Patients (or next-of-kin as appropriate) refuse to participate into the study

Related Conditions & MeSH terms

• Meningioma

Locations

Country	Name	City	State
Hong Kong	Department of Surgery, The Chinese University of Hong Kong	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whole exome sequencing data	DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.	7 days
Secondary	Immunostaining	H&E staining and meningioma markers immunostaining	7 days